Targeted Therapy Treatment Updates from ASCO 2022

2022-06-27T06:58:14-05:00June 27th, 2022|Hot Topics, Magnifying LeNS, Newsletter Articles, Science and Research|

Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]

FDA Approves Genentech’s Rozlytrek (entrectinib) for ROS1 Non-Small Cell Lung Cancer (NSCLC) and NTRK-Driven Tumors

2020-04-17T11:35:09-05:00August 16th, 2019|Hot Topics, News, Press Releases, Science and Research|

On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor [...]

Go to Top